Bioorganic and Medicinal Chemistry p. 747 - 757 (2018)
Update date:2022-08-11
Topics:
Liu, Jian
Qian, Chengbo
Zhu, Yehua
Cai, Jianguo
He, Yufang
Li, Jie
Wang, Tianlin
Zhu, Haohao
Li, Zhi
Li, Wei
Hu, Lihong
Both histone deacetylase (HDAC) and fibroblast growth factor receptor (FGFR) are important targets for cancer therapy. Although combining dual HDAC pharmacophore with tyrosine kinase inhibitors (TKIs) had achieved a successful progress, dual HDAC/FGFR1 inhibitors haven't been reported yet. Herein, we designed a series of hybrids bearing 1H-indazol-3-amine and benzohydroxamic acids scaffold with scaffold hopping and molecular hybridization strategies. Among them, compound 7j showed the most potent inhibitory activity against HDAC6 with IC50 of 34 nM and exhibited the great inhibitory activities against a human breast cancer cell line MCF-7 with IC50 of 9 μM in vitro. Meanwhile, the compound also exhibited moderate FGFR1 inhibitory activities. This study provides new tool compounds for further exploration of dual HDAC/FGFR1 inhibition.
View MoreAllyChem Co., Ltd., Dalian, China(BBChem)
Contact:+86-411-62313318/62313328
Address:No.5 of Jinbin Road, Jinzhou New District, Dalian City, Liaoning Province, P.R.China
Shanghai Yuantai Chemical Products Co., Ltd
Contact:021--66129803
Address:Chengyin Road,Shanghai,China
Jiangsu Glory Chemical Co., Ltd.
Contact:+86-571-87896791
Address:Yanhua Chemical Park, Hongze, Huai'an, Jiangsu, China
Contact:+86-20-62802632;62802633
Address:Room 330 GIGCAS Building,No.511 Kehua Street,Tianhe District
LianYunGang Chiral Chemical(CHINA) CO.,LTD
Contact:+86-518-83616958 +86-519-82884848
Address:LianYunGang Chemical Industry Park (JiangSu)
Doi:10.1016/0022-328X(92)80206-D
(1992)Doi:10.1016/S0031-9422(98)80075-7
(1998)Doi:10.1021/bm3015285
(2013)Doi:10.1080/14756366.2016.1232254
(2017)Doi:10.1248/cpb.28.1
(1980)Doi:10.1002/(SICI)1099-0682(199812)1998:12<1975::AID-EJIC1975>3.0.CO;2-K
(1998)